• J. Neurol. Neurosurg. Psychiatr. · Apr 2023

    SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.

    • Zoé L E van Kempen, Eileen W Stalman, Maurice Steenhuis, Laura Y L Kummer, Koos P J van Dam, Maarten F Wilbrink, Anja Ten Brinke, van HamS MariekeSMImmunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, location VUMC, Amsterdam, The Netherlands.Swammerdam Insitute for Life Sciences, Amsterdam UMC, Amsterdam, The Netherlands., Taco Kuijpers, Theo Rispens, Filip Eftimov, Luuk Wieske, Joep Killestein, and T2B! immunity against SARS-CoV-2 study group.
    • Neurology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands Z.vankempen@amsterdamumc.nl.
    • J. Neurol. Neurosurg. Psychiatr. 2023 Apr 1; 94 (4): 280283280-283.

    BackgroundIt is unclear which patients with multiple sclerosis (MS) are most susceptible for omicron breakthrough infections.MethodsWe assessed omicron breakthrough infections in vaccinated patients with MS with and without disease-modifying therapies enrolled in an ongoing large prospective study. We longitudinally studied humoral responses after primary and booster vaccinations and breakthrough infections.ResultsOmicron breakthrough infections were reported in 110/312 (36%) patients with MS, and in 105/110 (96%) infections were mild. Omicron breakthrough infections occurred more frequently in patients treated with anti-CD20 therapies and sphingosine-1 phosphate receptor (S1PR) modulators, patients with impaired humoral responses after primary immunisation (regardless of treatment) and patients without prior SARS-CoV-2 infections. After infection, antibody titres increased in patients on S1PR modulator treatment while anti-CD20 treated patients did not show an increase.ConclusionsSARS-COV-2 omicron breakthrough infections are more prevalent in patients with MS on anti-CD20 therapies and S1PR modulators compared with other patients with MS, which correlated with decreased humoral responses after vaccination. Humoral responses after infection were higher in S1PR modulator-treated patients in comparison to patients on anti-CD20 therapies, suggesting that immunological protection from contracting infection or repeated exposures may differ between these therapies.© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…